Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (640)	3/12/1999 9:27:00 AM
From: Tony van Werkhooven	Read Replies (1) \| Respond to of 1386

Hi David- I had not considered the issuance of shares to an HU211 partner. If so, then you are right- it becomes a tradeoff of costs and benefits. In particular, also to be considered is impact of any action on the float. Tony

To: David Israel-Rosen who wrote (640)	3/17/1999 1:36:00 PM
From: crysball	Read Replies (1) \| Respond to of 1386

TOP NEW STORY ON AOL-'MARAJUANA MEDICAL USE DESERVES MORE STUDY' The Associated Press is running a feature story today (which AOL has called their Top News Story, concerning the medical benefits of Marajuana. The article ends with a scientist calling for the synthesis and medical utilization of the active ingredients (cannaboids) with a variety of delivery systems such as inhalers. Hopefully Ariella will pick this up and contact AP and give them a feed on the pioneering PARS work and status of clinical trials. Financial PR is not just beating your own drum, but getting others to beat your drum for you. Let's see if Ariella can make hay while the sun is shining on the medical uses of Marajuana.